Grants and Contributions:
Title:
Development of RNA therapies for therapeutic modulation of expression
Agreement Number:
1033096
Agreement Value:
$75,000.00
Agreement Date:
Jul 15, 2025 - Jan 27, 2026
Description:
Scalable platform development for programmable genetic medicines, focused on high-throughput screening and functional validation in engineered cell models. The project enables rapid iteration and optimization of therapeutic candidates for severe neurological and metabolic diseases.
Organization:
National Research Council Canada
Expected Results:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Location:
Toronto, Ontario, CA M5G 1M1
Reference Number:
172-2025-2026-Q2-1033096
Agreement Type:
Contribution
Report Type:
Grants and Contributions
Recipient Business Number:
709922819
Recipient Type:
For-profit organization
Recipient's Legal Name:
Orb Therapeutics Inc.
Federal Riding Name:
University--Rosedale
Federal Riding Number:
35110
Program:
Industrial Research Assistance Program – Contributions to Firms
Program Purpose:
The purpose of IRAP Contributions to Firms is to support research, development, adoption and/or adaptation of innovative or technology-driven new or improved products, services or processes in Canada up to their commercialization
Coverage:
IRAP Contributions to Firms projects stimulate wealth creation for Canada through technological innovation.
NAICS Code:
541710